{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:37:19Z","timestamp":1767890239165,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electronic medical records from a regional medical centre in southern Taiwan to follow-up 441 patients newly diagnosed with common B-NHL subtypes: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia\/Small Lymphocytic Lymphoma (CLL\/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenstr\u00f6m macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2013, until 31-Dec-2017. Treatment pathways were modelled using a Markov approach. Stage III\/IV disease at diagnosis was frequent for patients with\u00a0DLBCL, FL, MCL and WM. Hepatitis B surface antigen\/hepatitis C virus seropositivity was 18.6%\/12.3%. Clinical responses to 1st-line treatment were observed in 76.0% (DLBCL), 87.3% (FL), 86.0% (MZL), 60.0% (MCL), and\u00a042.9% (WM)\u00a0of patients. For DLBCL, disease control was achieved by\u2009~\u200950% after 1st-line,\u2009~\u200924% after 2nd-line,\u2009~\u200917% after 3rd-line. Patients with Stage III\/IV DLBCL or age\u2009&gt;\u200965\u00a0years at diagnosis had lower rates of active treatment, poorer disease control and higher mortality than patients with early stage disease or age\u2009\u2264\u200965\u00a0years. Disease flare\u2009&lt;\u20096\u00a0months after 1st-line treatment was significantly associated with mortality. Despite good clinical response rates for some sub-types, survival remains poor. New treatments are needed to improve the outcome of B-NHL.<\/jats:p>","DOI":"10.1038\/s41598-021-89316-y","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T10:03:45Z","timestamp":1620813825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-7711","authenticated-orcid":false,"given":"Sung-Nan","family":"Pei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Kai","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Anne","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"89316_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage, J. O., Gascoyne, R. D., Lunning, M. A. & Cavalli, F. Non-Hodgkin lymphoma. Lancet 390, 298\u2013310 (2017).","journal-title":"Lancet"},{"key":"89316_CR2","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles, G. et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv. Ther. 34, 2232\u20132273 (2017).","journal-title":"Adv. Ther."},{"key":"89316_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.hoc.2019.03.007","volume":"33","author":"AF Herrera","year":"2019","unstructured":"Herrera, A. F. Noncellular immune therapies for non-Hodgkin lymphoma. Hematol. Oncol. Clin. N. Am. 33, 707\u2013725 (2019).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"89316_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"89316_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen, R. G. et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth international workshop. Br. J. Haematol. 160, 171\u2013176 (2013).","journal-title":"Br. J. Haematol."},{"key":"89316_CR6","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier, B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116, 2040\u20132045 (2010).","journal-title":"Blood"},{"key":"89316_CR7","unstructured":"Gagniuc, P. Markov Chains: From Theory to Implementation and Experimentation 1\u2013256 (Wiley, 2017). ISBN 978-1-119-38755-8."},{"key":"89316_CR8","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J. Clin. Oncol. 33, 2516\u20132522 (2015).","journal-title":"J. Clin. Oncol."},{"key":"89316_CR9","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1182\/blood.V99.12.4265","volume":"99","author":"JJ Biagi","year":"2002","unstructured":"Biagi, J. J. & Seymour, J. F. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 99, 4265\u20134275 (2002).","journal-title":"Blood"},{"key":"89316_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canep.2016.02.007","volume":"42","author":"BA Bassig","year":"2016","unstructured":"Bassig, B. A. et al. Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001\u20132010. Cancer Epidemiol. 42, 15\u201323 (2016).","journal-title":"Cancer Epidemiol."},{"key":"89316_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li, S., Young, K. H. & Medeiros, L. J. Diffuse large B-cell lymphoma. Pathology 50, 74\u201387 (2018).","journal-title":"Pathology"},{"key":"89316_CR12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith, A. et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s haematological malignancy research network. Br. J. Cancer 112, 1575\u20131584 (2015).","journal-title":"Br. J. Cancer"},{"key":"89316_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/ajh.20649","volume":"81","author":"MY Lee","year":"2006","unstructured":"Lee, M. Y., Tan, T. D., Feng, A. C. & Liu, M. C. Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am. J. Hematol. 81, 568\u2013575 (2006).","journal-title":"Am. J. Hematol."},{"key":"89316_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"AM Perry","year":"2016","unstructured":"Perry, A. M. et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica 101, 1244\u20131250 (2016).","journal-title":"Haematologica"},{"key":"89316_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","volume":"95","author":"K Matsuo","year":"2004","unstructured":"Matsuo, K. et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin\u2019s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 95, 745\u2013752 (2004).","journal-title":"Cancer Sci."},{"key":"89316_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","volume":"106","author":"CH Chen","year":"2007","unstructured":"Chen, C. H. et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J. Formos Med. Assoc. 106, 148\u2013155 (2007).","journal-title":"J. Formos Med. Assoc."},{"key":"89316_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jhep.2015.03.013","volume":"63","author":"CL Chen","year":"2015","unstructured":"Chen, C. L. et al. Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan. J. Hepatol. 63, 354\u2013363 (2015).","journal-title":"J. Hepatol."},{"key":"89316_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/jvh.12713","volume":"24","author":"CE Huang","year":"2017","unstructured":"Huang, C. E. et al. The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. J. Viral Hepat. 24, 885\u2013894 (2017).","journal-title":"J. Viral Hepat."},{"key":"89316_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2796.2009.02083.x","volume":"265","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri, A. J., Ernberg, I. & Copie-Bergman, C. Infectious agents and lymphoma development: molecular and clinical aspects. J. Intern. Med. 265, 421\u2013438 (2009).","journal-title":"J. Intern. Med."},{"key":"89316_CR20","doi-asserted-by":"publisher","first-page":"e0115836","DOI":"10.1371\/journal.pone.0115836","volume":"10","author":"CY Chen","year":"2015","unstructured":"Chen, C. Y., Huang, K. Y., Shen, J. H., Tsao, K. C. & Huang, Y. C. A large-scale seroprevalence of Epstein-Barr virus in Taiwan. PLoS ONE 10, e0115836 (2015).","journal-title":"PLoS ONE"},{"key":"89316_CR21","unstructured":"International Agency for Research on Cancer, Swerdlow S. H. (ed) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edn (2017)."},{"key":"89316_CR22","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","volume":"20","author":"M Hamadani","year":"2014","unstructured":"Hamadani, M. et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 20, 1729\u20131736 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"89316_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/bjh.14822","volume":"179","author":"L Modvig","year":"2017","unstructured":"Modvig, L., Vase, M. & d\u2019Amore, F. Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. Br. J. Haematol. 179, 75\u201382 (2017).","journal-title":"Br. J. Haematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89316-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:59:59Z","timestamp":1670054399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89316-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89316"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89316-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"16 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SNP received a Grant from Janssen Research & Development LLC to conduct the study. LAR, HQ and YL are employees of Janssen Research & Development and report stock ownership in Johnson & Johnson Pte. Ltd. MCW, MCM, CHK and CKL declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10069"}}